ArticleArchives of oral biology2026
Sustained insulin-delivery as a growth factor for modulating oral mucosa healing: A case series.
Article in Archives of oral biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objective(s): In clinical practice, achieving a smooth recovery is essential, with an emphasis on optimizing therapeutic outcomes and ensuring patient comfort. The use of targeted therapies to modulate the host response toward resolution is highly desirable. Thus, this study aims to evaluate a novel sustained insulin-delivery system (DS) as a growth factor for oral wounds, integrating device characterization, in vitro and clinical assessments, and focusing on the modulation of the oral mucosa healing.
designThe device was evaluated for thickness, water vapor permeability, scanning electron microscopy, tensile strength, swelling degree, and insulin in vitro release in human saliva. Cytotoxicity and genotoxicity were assessed using Human Epidermal Keratinocyte (HaCat), Foreskin Fibroblast (HFF-1), and Gingival Fibroblast (HGF) cells. The 3-month outcomes of palatal wound healing following free gingival graft harvesting in twelve patients, using the DS, were evaluated through clinical and immunological parameters.
resultsThe DS exhibited great permeability, elasticity, and a rough surface. It demonstrated an exponential insulin release during the first 12 h, delivering 30% of its content. Afterwards, a controlled diffusional mechanism was achieved, leading to sustained delivery over 3 days. No cyto/genotoxicity was observed in cell types. No adverse effects were observed during the clinical use of the biomaterial. Clinical outcomes showed accelerated palatal wound closure along with increased epithelialization on days 7 and 14 posttherapy (p < 0.001). The DS application did not elicit a pro-inflammatory response.
conclusionsDS displayed suitable physical properties for oral application, low cytotoxicity/genotoxicity, and favorable clinical outcomes. Its efficacy warrants validation in future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.